Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, DeBruin E, Barry ST. Hopcroft L, et al. Among authors: carnevalli ls. NPJ Breast Cancer. 2023 Aug 18;9(1):69. doi: 10.1038/s41523-023-00575-6. NPJ Breast Cancer. 2023. PMID: 37596288 Free PMC article. No abstract available.
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Floc'h N, Ashton S, Ferguson D, Taylor P, Carnevalli LS, Hughes AM, Harris E, Hattersley M, Wen S, Curtis NJ, Pilling JE, Young LA, Maratea K, Pease EJ, Barry ST. Floc'h N, et al. Among authors: carnevalli ls. Mol Cancer Ther. 2019 May;18(5):909-919. doi: 10.1158/1535-7163.MCT-18-0577. Epub 2019 Mar 14. Mol Cancer Ther. 2019. PMID: 30872381
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.
Taylor MA, Hughes AM, Walton J, Coenen-Stass AML, Magiera L, Mooney L, Bell S, Staniszewska AD, Sandin LC, Barry ST, Watkins A, Carnevalli LS, Hardaker EL. Taylor MA, et al. Among authors: carnevalli ls. J Immunother Cancer. 2019 Nov 28;7(1):328. doi: 10.1186/s40425-019-0794-7. J Immunother Cancer. 2019. PMID: 31779705 Free PMC article.
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Carnevalli LS, Taylor MA, King M, Coenen-Stass AML, Hughes AM, Bell S, Proia TA, Wang Y, Ramos-Montoya A, Wali N, Carroll D, Singh M, Moschetta M, Gutierrez PM, Gardelli C, Critchlow SE, Klinowska T, Fawell SE, Barry ST. Carnevalli LS, et al. Mol Cancer Ther. 2021 Jun;20(6):1080-1091. doi: 10.1158/1535-7163.MCT-20-0961. Epub 2021 Mar 30. Mol Cancer Ther. 2021. PMID: 33785652
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: carnevalli ls. NPJ Breast Cancer. 2023 Aug 5;9(1):64. doi: 10.1038/s41523-023-00571-w. NPJ Breast Cancer. 2023. PMID: 37543694 Free PMC article.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: carnevalli ls. NPJ Breast Cancer. 2023 Sep 19;9(1):76. doi: 10.1038/s41523-023-00581-8. NPJ Breast Cancer. 2023. PMID: 37726304 Free PMC article. No abstract available.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembé AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST. Hardaker EL, et al. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4. Nat Commun. 2024. PMID: 38402224 Free PMC article.
31 results